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tiveness of SNM versus OMT and BonT-A.METHODS:AMarkovmodel withMonte-
Carlo simulation was used to assess the ICER of SNM vs. BonT-A and OMT both in
deterministic (base-case) and probabilistic (sensitivity) analysis from a provincial
payer perspective over a 10-year time horizon with 9 month Markov-cycles. Clini-
cal data, healthcare resource utilization and utility scores were acquired from re-
cent publications and an expert panel of 7 surgeons. Cost data (2011 Dollars) were
derived from provincial health insurance policy, drug benefit formulary and hos-
pital data. All cost and outcomeswere discounted at 3% rate. RESULTS: The annual
(year 1-10) incremental QALY for SNM vs. BonT-A was 0.05-0.51 and SNM versus
OMTwas 0.19-1.76. The annual incremental cost of SNM versus BonT-Awas $7,237
in year-1 and -$9,402 in year-10 andwas between $8,878 to -$11,447 vs. OMT. In the
base-case deterministic analysis, the ICER for SNM vs. BonT-A and OMT were
within the acceptable range ($44,837 and $15,130 respectively) at 2nd-year of ther-
apy, and SNM was dominant in consequent years. In the base-case analysis the
probability of ICER being below the acceptability curve of (Willingness-To-
Pay$50,000) was 99% for SNM versus BonT-A at year 3 and 95% for OMT at
year-2. CONCLUSIONS: SNM is a cost-effective treatment option for the manage-
ment of patients with refractory OAB when compared to either BonT-A or OMT.
From a Canadian payers’ perspective, SNM should be considered as first-line treat-
ment option in management of patients with OAB.
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OBJECTIVES: Drug-eluting stents (DES) reduce the need for target repeat revascu-
larization (TVR) compared with bare metal stents (BMS) but are two to three more
expensive. We aim to assess the cost-effectiveness of DES in Hong Kong.
METHODS: Consecutive patients undergoing percutaneous coronary intervention
(PCI) at our institution from September 2009 to September 2010 were evaluated.
Clinical outcomewasmeasured by the occurrence of major adverse cardiac events
(MACE), including death, myocardial infarction and clinically driven TVR. Direct
healthcare costs for index procedure, TVR, and follow-up costs were assessed. An
EQ-5D questionnaire was used to measure quality of life for the baseline and 6
months post PCI. Themain outcomewas the incremental cost-effective ratio (ICER)
for additional cost per TVR avoid and per quality-adjusted life-year (QALY) gained.
Costs are expressed inUS dollars (1USD 7.7HKD).RESULTS:A total of 761 patients
(DES476, BMS285) were evaluated. Clinically driven TVR occurred in 3.6% and
4.2%ofDES andBMSpatients, respectively (p0.68). One year total healthcare costs
was higher for DES patients (US$13,303) than BMS patients (US$12,075, p0.01).
Both groups experienced significant improvement in health utility score at 1 year
compared to baseline but therewas no significant difference betweenDES and BMS
patients (p0.07). QALY gained for DES and BMS patients were 0.415 and 0.375,
respectively (p0.61). The incremental cost per QALY gained was US$30,700 and
per TVR avoided was US$204,667. CONCLUSIONS: In this real-world PCI registry,
the use of DES was associated with significant improvement in quality of life and
low TVR rates which were similar in comparison with BMS. Based on these results,
DES can be considered cost-effective in terms of QALY gained but not for additional
TVR avoided in Hong Kong.
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COLONOSCOPY IN 40 TO 49-YEAR-OLD SYMPTOMATIC PATIENTS
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OBJECTIVES: Early diagnosis of colorectal cancer (CRC) has been shown to improve
life expectancy, and colonoscopy and sigmoidoscopy are cost effective techniques
for CRC diagnosis in older age groups. The objective of this study was to determine
the cost-effectiveness (i.e., cost per QALY) of performing sigmoidoscopy, to check
for neoplasms in the distal colon, before performing colonoscopy in a group of
symptomatic 40-49 year old patients fromaUS societal perspective.METHODS: Los
Angeles County colonoscopy data was reviewed for symptomatic patients without
a family history of CRC to obtain neoplasm rates (N883). Records were collected
from April 2003 to April 2008. Additional parameters for the decision tree analysis
were extracted from a systematic literature review. RESULTS: Diagnostic sigmoid-
oscopy (DS) followed by diagnostic colonoscopy (DC) in patients with a distal ad-
vanced neoplasmwas shown to be themost cost-effective strategy (ICER$48,368),
DS followed by DC in patients with any distal neoplasmwas next (ICER$157,114),
and DC for all symptomatic patients was the least cost-effective (ICER$184,724).
DS followed by DC in patients with any distal neoplasm was sometimes less cost-
effective than DC for all symptomatic patients in a one-way sensitivity analysis. A
threshold analysis was completed for the cost of colonoscopy. CONCLUSIONS: DS
followed by DC in patients with distal advanced neoplasm was shown to be cost-
effective at a $50,000 willingness-to-pay threshold. The other diagnostic strategies
did not meet that threshold. Although, DS followed by DC in patients with any
distal neoplasms nearly met a threshold of $150,000. All strategies were most sen-
sitive to the stage of CRC at diagnosis and the prevalence of patientswith advanced
neoplasm. A colonoscopy cost reduction of over 40%was necessary tomake DC for
all symptomatic patients a cost-effective strategy at a $50,000 threshold and over
25% at a $100,000 threshold.
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OBJECTIVES:To evaluate cost-effectiveness of the implementation, in Colombia, of
different screening strategies for colorectal cancer (CRC): fecal occult blood stool
guaiac test (OB-GT), fecal occult blood immunochemical test (OB-IT), conventional
colonoscopy, sigmoidoscopy, OB-GT followed by sigmoidoscopy, and OB-IT test
plus sigmoidoscopy. METHODS: We designed a Markov model representing the
natural history of CRC in adult Colombians, for the whole lifespan of each individ-
ual, in one-year cycles, using local demographic and epidemiological data. This
model was then modified for each of the screening strategies, assuming detection
rates based on systematic review of the literature. Direct medical costs, from the
Colombian health system perspective (third-party payer), were estimated using
base-case data analysis from the Instituto Nacional de Cancerología (the Colom-
bian national cancer reference center) and applying two different national tariff
manuals (locally known as SOAT and ISS-2001). The costs assigned to each screen-
ing strategy included other diagnostic procedures included in standard protocols
as well as therapy for pre-neoplasic or cancer therapy at different stages of the
disease. A strategy was considered cost-effective if an incremental life year gained
(LYG) costs up to three times the per capita GDP of US$6225. Discount rate was 3%,
for costs and LYG. RESULTS: The cost in US$ per LYG differedmarkedly depending
on the tariff manual used. In both cases, however, biennial OB-GT was cost-effec-
tive (US$10,641 and US$2,694 per LYG), compared with annual OB-GT (US$ 18,902
and US$27,237 per LYG), and biennial OB-IT (US$46.439 and US$14.040 per LYG).
Other screening strategies were clearly not cost-effective under our assumptions.
Probabilistic sensitivity analysis did not change results significantly.
CONCLUSIONS: The most cost-effective screening strategy for CRC in Colombia
(and the only one below our threshold) was biennial feccal occult blood guaiac test.
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OBJECTIVES: Gefitinib, selective epidermal growth factor receptor tyrosine kinase
inhibitor improves progression free survival and overall survival for non-small-cell
lung cancer (NSCLC) patients. However patients with EGFR gene wild-type don’t
benefit from gefitinib. METHODS: We performed cost-effectiveness analysis of
EGFR testing and gefitinib treatment as first-line therapy for NSCLC patients. In our
analysis, we considered three groups:(A) gefitinib treatment for all the patients
without EGFR testing, (B) chemotherapy (carboplatin / paclitaxel) for all the pa-
tients without EGFR testing, and (C) gefitinib treatment for mutation patients and
chemotherapy(carboplatin / paclitaxel) for wild-type patients with EGFR testing.
The cost-effectiveness of two comparison groups was calculated: group A vs. C
(cost-effectiveness of EGFR testing) and and group B versus C (cost-effectiveness of
gefitinib treatment with EGFR testing). Outcome of gefitinib or chemotherapy was
based on Iressa Pan-Asia Study (IPASS) [FukuokaM et al. (2011)]. Onlymedical costs
were included from the perspective of Japanese healthcare payer (the cost of EGFR
testing is JPY 20,000 (USD 260, 1USDJPY77). Discount wasn’t performed because
of short time horizon. RESULTS: ICER of gefitinib with EGFR testing was JPY 900,000
(USD 12,000) (groupA vs. C) per life year gained (LYG) and the ICER of chemotherapy
with EGFR testing was JPY 3,580,000 (USD 46,500) (group B vs. C) per LYG. The cost
of EGFR testing was not influenced on the results. If the cost of EGFR testing is
increased to JPY 80,000 (USD 1,000), the ICER was changed to JPY 1,100,000 (USD
14,000) (group A vs. C) per LYG and JPY 4,870,000 (USD 63,000) per LYG, respectively.
CONCLUSIONS: EGFR testing is cost-effective, however it is not clearly shown that
gefitinb is cost-effective even if EGFR testing is used. EGFR testing is also recom-
mended from the economic perspective if gefitinib is considered to be adminis-
tered.
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OBJECTIVES:Weaim to evaluate the cost-effectiveness of drug-eluting stents (DES)
in a real world setting of multi-vessel percutaneous coronary intervention (PCI).
METHODS: We analyzed 795 consecutive patients undergoing PCI at our institu-
tion. Health outcomeswas estimated in terms of quality adjusted life years (QALYs)
gained measured using EQ-5D at baseline, 6 and 12 months after PCI. Total direct
healthcare costs including cost of index procedure and follow-up costs incurred
over 12 months were calculated. Incremental cost-effective ratio (ICER) per QALY
gained was used to evaluate the cost-utility of DES. RESULTS: Of the 795 patients,
482, 201 and 61 patients underwent single-, 2- and 3-vessel PCI, respectively. DES
was used in 62.7%, 62.6%, 58.7% and 68.9% in overall, single-, 2- and 3-vessel PCI
procedures, respectively. There was progressive increase in QALY gain for patients
who had PCI to 3- (0.43) than in 2- (0.40) and 1-vessel (0.39, p0.01). DES was
associated with higher 1 year total healthcare cost in all 3 groups but was more
effective only in patientswhounderwent 2- and 3-vessel PCIwith an ICER perQALY
gained of US$3,131 and US$21,290, respectively. CONCLUSIONS: In this real-world
A67V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
PCI registry, despite higher total healthcare costs, the use of DESwas cost-effective
in patients who underwent 2- and 3-vessel PCI than in single vessel PCI.
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OBJECTIVES: In vitro diagnostic (IVD) has a considerable health economic impact:
60% of patients’ information derives from IVD tests, but IVD makes 1% of the total
health care budget in EU (EDMA, 2010). No cost-effectiveness (CE) analyses are
available onmolecular IVD in allergy; only NICE in the UKmade a CE study IgE IVD
for peanut allergy (PA). Given the impact of PA on quality of life (Qaly), accurate
diagnosis is crucial. 10%of children are considered peanut sensitised, but only 1-2%
is true positive for PA. Subjects with IgE antibodies to allergens Ara h1-2-3 have
high risk of allergic reactions (Astier, 2006). DBPCFC is the gold standard for food-
allergy diagnosis; however it is time-consuming, expensive and might induce se-
vere reactions (Nicolau, 2010). IVD can give clinicians a tool to decide the need of
DBPCFC (Sastre, 2010); is IVD CE compared to DBPCFC in suspected PA children in
EU, US and Japan?METHODS: Data was collected at Stockholm’s Sach=s Children’s
hospital (Nilsson, 2011) and from published literature. A 5-year Markov simulation
model comparing IVD (ImmunoCap® - allergens f13, Ara h 1- 2-3-8-9) with DBPCFC
was developed with Tree AgePro®, to analyse CE for IVD and the incremental cost
per Qaly in suspected PA children. The sensitivity and specificity of each diagnos-
tics determines the percentage of patients true-allergic, false-allergic, true-healthy
and false-healthy. BaseCase® was used to interactively visualize results. Results
are presented from the health care perspective; care giver indirect costs are in-
cluded in a sensitivity analysis. RESULTS: IgE IVD is CE and cost saving for children
with suspected PA in multiple countries compared to golden standard DBPCFC.
CONCLUSIONS: IVD is a CE alternative to DBPCFC in selected patients in multiple
countries. DBPCFCmight be replaced in selected cases, still being useful in subjects
with conflicting immunological/clinical results (Codreanu, 2011).
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OBJECTIVES:Wound complications following surgical procedures are a significant
cost burden to the health care system and have been identified as one of the
hospital-acquired infections not reimbursed by payers. Surgical site infections
have been associated with both an increased hospital stay of 9.58 extra days and
$38,656 in additional medical charges, and postoperative dehiscence can add as
much as 9.42 extra days, resulting in $40,323 in additional charges. A health eco-
nomicmodel was developed to demonstrate potential cost savings associatedwith
using closed incision management (CIM*) to apply negative pressure wound ther-
apy (NPWT) over clean closed surgical incisions in patients treated for an open
fracture of the tibia and fibula. METHODS: The hypothetical economic model ap-
plied national cost dollars to clinical outcomes of the Stannard et al randomized
controlled trial (RCT) usingNPWT†over closed incisions. National cost data (Thom-
son Reuters custom report) were selected using the diagnosis codes related to the
population of patients within the Stannard et al RCT, which were open fracture of
the tibia and fibula with complications such as infection and dehiscence (ICD9
79.36). The infection rates (10%, 14/141 patients NPWT and 19%, 23/122 patients
Control [standard of care], p0.049) and dehiscence rates (8.6%, 12/141 NPWT and
16.5%, 20/122 Control, p0.044) were calculated from the Stannard et al RCT and
were applied to a hypothetical 100 patient population (50 CIM and 50 Control).
RESULTS: Reduced infection and dehiscence rates in this patient population re-
sulted in potential per patient cost savings of $5338 for infection and $1586 for
dehiscence with CIM. CONCLUSIONS: These findings illustrate the potential cost
effectiveness of CIM over closed incisions of high-risk fractures. *Prevena™ Inci-
sion Management System and †V.A.C. Therapy; KCI USA, Inc., San Antonio, TX,
USA
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Current available methods in Mexico for blood group typing are made through a
tube serological antigen/antibody reaction (TST) but has limitations due to the lack
of blood weak antigens detection that generate incomplete information on blood
group phenotype and potential recipient alloimmunization that can cause life
threatening transfusion-related reactions as acute lung injury and hemolytic
reactions. OBJECTIVES: To develop an economic model based in Mexican Institute
of Social Security (IMSS) resource payments to evaluate the cost-effectiveness of
ANDCK versus TST for the determination of blood erythrocyte variants in Mexico.
METHODS: A two branch decision tree model was developed to evaluate and com-
pare the cost-effectiveness in Mexican pesos (MxP) of ANDCK and TST for the
determination of blood erythrocyte variants. The effectivenessmeasure was blood
group typing errors rate obtained from published clinical trials. Resource use and
cost were obtained from expert interviews and IMSS published data respectively.
The model estimated cost per patient and incremental cost-effectiveness ratios
(ICER). Costs and effectiveness do not were discounted. A deterministic sensitivity
analysis was also performed. RESULTS: The rate of blood group typing errors was
0.07% for ANDCK group and 0.17% for TST group. Cost per patientwas always lower
with ANDCK ($2,340.00 MxP) than TST ($3,921.21 MxP) showing that ANDCK was
the dominant alternative. Sensitivity analysis shows model robustness and con-
firms ANDCK as dominant alternative. CONCLUSIONS: Our results show that
ANDCK is cost-effective for the determination of blood erythrocyte variants in
Mexico and should be considered by clinicians and decision makers as a favorable
option for the determination of blood group typing in order to avoid life threatening
transfusion-related reactions.
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TO PREVENT CENTRAL-LINE ASSOCIATED BLOODSTREAM INFECTIONS AND
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OBJECTIVES: The objective of the study was to evaluate the economic impact of
adding the use of chlorhexidine gluconate (CHG) impregnated sponge dressings to
Canadianhospitals’ standard infection prevention routine. The current standard of
care for catheter insertion in Canada involves hand hygiene, skin preparation and
transparent film dressings. The aim of this study was to determine whether the
addition of CHG impregnated sponge dressings to catheter insertion procedurewas
cost-effective. METHODS: The economic model was populated with clinical and
economic data obtained from peer-reviewed literature along with case-costing
data froma large Canadian hospital network. One and twoway sensitivity analyses
were conducted on economic and clinical parameters to ensure robustness.
RESULTS: Based on model calculations using a hypothetical hospital with 400 in-
patient beds and 20 intensive care unit beds, the use of CHG dressings would
reduce the number of CLABSIs from 107 to 43 annually, and would reduce the
number of local site infections from 430 to 258 annually. The model demonstrates
cost savings through the reduction of CLABSI and local site infections as well as
through decreased nursing costs. Themodel establishes that the use of CHG dress-
ings has the potential to provide $869, 867.49 of net cost savings in one hospital per
year. CONCLUSIONS: The use of chlorhexidine gluconate impregnated sponge
dressings for central venous and arterial catheter insertion sites proves to be a
cost-effective intervention in Canadian hospitals.
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OBJECTIVES: The aim of this study is to evaluate the cost-effectiveness of CT cor-
onary angiography (CTCA) and myocardial SPECT for ischemic heart disease in
patients with chest pain.METHODS:We assessed cost-effective of CTCA andmyo-
cardial SPECT for patients with intermediate risk with pre-test likelihood of 10-90.
The model was analyzed by using diagnosis accuracy and QALY. The model using
diagnosis accuracy used the number of patients accurately diagnosed among 1000
persons as the effect, and reflecting only themedical expenses for tests as the cost.
In the model using QALY, a decision tree was developed and the time horizon was
1 year. Utility weights were calculated using questionnaires for each case from
general population. Costs were calculated through analysis of Health Insurance
Review & Assessment Service claim data and transition probabilities were esti-
mated from retrospective cohort data. Analyses were conducted from the Health-
care system perspectives. RESULTS: In the model using diagnosis accuracy, CTCA
appeared to be more effective (224.41 correct diagnosis) and even less expensive
(US$58,819 per 1,000 persons) thanmyocardial SPECT proposed to be the dominate
alternative. In themodel using QALY, CTCA showedmore effective (0.00040QALYs)
and less cost (US$465) than myocardial SPECT. Sensitivity analysis was performed
for transition probabilities, utilityweights and costs. The results of sensitivity anal-
ysis were robust. In subgroup analysis, myocardial SPECT showed cost-effective in
patients with pre-test likelihood of 30-60. CONCLUSIONS: In conclusion, cost-ef-
fective analysis between CTCA andmyocardial SPECT indicated that CTCAwas the
cost-effective test for both models using diagnosis accuracy and the one using
QALY in patients with intermediate risk with pre-test likelihood of 10-90.
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OBJECTIVES: The cost implications of adopting portablemonitoring devices for the
diagnosis of obstructive sleep apnea (OSA) are largely unknown.We conducted an
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